Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. (3r,4s,5s,6r)-5-methoxy-4-((2r,3r)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl)-1-oxaspiro(2.5)oct-6-yl (2e)-3-(4-(2-(dimethylamino)ethoxy)phenyl)acrylate
2. Ckd-732
3. Ckd732
4. O-(4-dimethylaminoethoxycinnamoyl)fumagillol
1. 251111-30-5
2. Beloranib [inn]
3. Zgn-433
4. Zgn-440
5. Ckd-732
6. Zgn 440
7. O-[4-(2-dimethylaminoethoxy)-trans-cinnamoyl]fumagillol
8. Fi471k8bu6
9. (3r,4s,5s,6r)-5-methoxy-4-((2r,3r)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro(2.5)octan-6-yl (2e)-3-(4-(2-(dimethylamino)ethoxy)phenyl)prop-2-enoate
10. O-(4-(2-dimethylaminoethoxy)-trans-cinnamoyl)fumagillol
11. 609845-93-4
12. Unii-fi471k8bu6
13. Zgn 433
14. [(3r,4s,5s,6r)-5-methoxy-4-[(2r,3r)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] (e)-3-[4-[2-(dimethylamino)ethoxy]phenyl]prop-2-enoate
15. Zgn-440(beloranib)
16. O-(4-dimethylaminoethoxycinnamoyl)fumagillol
17. Beloranib [who-dd]
18. Gtpl8445
19. Us9682965, Compound A
20. Chembl4297504
21. Schembl14648763
22. Dtxsid40179800
23. Bdbm148430
24. Zgn-440;cdk-732
25. Zinc3982162
26. Db12671
27. (3r,4s,5s,6r)-5-methoxy-4-((2r,3r)-2-methyl-3-(3-methyl-2-buten-1-yl)-2-oxiranyl)-1-oxaspiro(2.5)oct-6-yl (2e)-3-(4-(2-(dimethylamino)ethoxy)phenyl)acrylate
28. Hy-14811
29. Cs-0003572
30. A13870
31. Q4884554
32. [(3r,4s,5s,6r)-5-methoxy-4-[(2r,3r)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] (e)-3-[4-(2-dimethylaminoethoxy)phenyl]prop-2-enoate
33. 3-[4-[2-(dimethylamino)ethoxy]phenyl]acrylic Acid (3r)-4beta-[(2r,3r)-2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-5alpha-methoxy-1-oxaspiro[2.5]octane-6alpha-yl Ester
| Molecular Weight | 499.6 g/mol |
|---|---|
| Molecular Formula | C29H41NO6 |
| XLogP3 | 4.4 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 12 |
| Exact Mass | 499.29338803 g/mol |
| Monoisotopic Mass | 499.29338803 g/mol |
| Topological Polar Surface Area | 73.1 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 815 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Angiogenesis Inhibitors
Agents and endogenous substances that antagonize or inhibit the development of new blood vessels. (See all compounds classified as Angiogenesis Inhibitors.)
ABOUT THIS PAGE
54
PharmaCompass offers a list of Beloranib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Beloranib manufacturer or Beloranib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Beloranib manufacturer or Beloranib supplier.
PharmaCompass also assists you with knowing the Beloranib API Price utilized in the formulation of products. Beloranib API Price is not always fixed or binding as the Beloranib Price is obtained through a variety of data sources. The Beloranib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Beloranib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Beloranib, including repackagers and relabelers. The FDA regulates Beloranib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Beloranib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Beloranib supplier is an individual or a company that provides Beloranib active pharmaceutical ingredient (API) or Beloranib finished formulations upon request. The Beloranib suppliers may include Beloranib API manufacturers, exporters, distributors and traders.
Beloranib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Beloranib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Beloranib GMP manufacturer or Beloranib GMP API supplier for your needs.
A Beloranib CoA (Certificate of Analysis) is a formal document that attests to Beloranib's compliance with Beloranib specifications and serves as a tool for batch-level quality control.
Beloranib CoA mostly includes findings from lab analyses of a specific batch. For each Beloranib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Beloranib may be tested according to a variety of international standards, such as European Pharmacopoeia (Beloranib EP), Beloranib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Beloranib USP).